We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
-9.33%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$363M
AUM Growth
-$71.1M
(-16%)
Cap. Flow
-$32.9M
Cap. Flow
% of AUM
-9.07%
Top 10 Holdings %
Top 10 Hldgs %
99.83%
Holding
15
New
1
Increased
1
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Innoviva
INVA
|
+$20.7M |
| 2 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
+$9.08M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$29M |
| 2 |
Pacira BioSciences
PCRX
|
+$14.7M |
| 3 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$7.87M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$4.45M |
| 5 |
Quest Diagnostics
DGX
|
+$4.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $160M | 44.03% |
12,850,000
| – | – |
|
2
Biogen
BIIB
$30B
| $87.9M | 24.21% |
310,000
| – | – |
|
|
MDCO
3
DELISTED
Medicines Co
MDCO
| $59.5M | 16.38% |
1,752,000
| – | – |
|
|
4
Innoviva
INVA
$1.55B
| $31.8M | 8.77% |
2,975,000
+1,975,000
| +198% | +$20.7M |
|
|
NVLN
5
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $8.63M | 2.38% |
+1,025,000
| New | +$9.08M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.43M | 1.5% |
360,000
-315,000
| -47% | -$4.45M |
|
|
ADXS
7
DELISTED
Advaxis Inc
ADXS
| $3.58M | 0.99% |
33,333
-6,667
| -17% | -$900K |
|
|
VVUS
8
DELISTED
Vivus Inc
VVUS
| $2.96M | 0.82% |
257,394
| – | – |
|
|
SEEL
9
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $1.88M | 0.52% |
13
| – | – |
|
|
AVEO
10
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $917K | 0.25% |
170,000
-30,000
| -15% | -$200K |
|
11
AbbVie
ABBV
$443B
| $626K | 0.17% |
10,000
-22,000
| -69% | -$1.34M |
|
|
12
Quest Diagnostics
DGX
$25.7B
| – | – |
-50,000
| Closed | -$4.23M |
|
|
13
Pacira BioSciences
PCRX
$1.04B
| – | – |
-430,000
| Closed | -$14.7M |
|
|
ARRY
14
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-4,300,000
| Closed | -$29M |
|
|
AEGR
15
DELISTED
Aegerion Pharmaceuticals
AEGR
| – | – |
-2,649,000
| Closed | -$7.87M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q4 2016 Portfolio in Review
As of Q4 2016, Sarissa Capital Management held 15 positions worth $363M, down 16% from $434M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management withdrew a net $32.9M in Q4 2016, closing 4 positions and reducing 4 holdings. Its most notable exit was Array Biopharma Inc, an estimated $29M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier.
Against the trend, Sarissa Capital Management opened a new position in Novelion Therapeutics Inc. Common Shares worth $8.63M.
- Sarissa Capital Management's largest Q4 2016 buy was Novelion Therapeutics Inc. Common Shares: 1,025,000 shares worth $8.63M.
- Sarissa Capital Management added most to Innoviva in Q4 2016, an estimated $20.7M increase.
- Sarissa Capital Management's biggest Q4 2016 reduction was Intra-Cellular Therapies Inc., cutting an estimated $4.45M.
- Sarissa Capital Management fully exited Array Biopharma Inc in Q4 2016, selling an estimated $29M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $363M portfolio in Q4 2016.
- Sarissa Capital Management opened 1 new position and closed 4 in Q4 2016.
- Sarissa Capital Management's portfolio value fell 16% quarter-over-quarter to $363M.
Based on Sarissa Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.